AZN - AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy | Benzinga
AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC-2 Phase 3 trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of progression-free survival versus CRT alone for unresectable, Stage III non-small cell lung cancer.
Imfinzi sequentially administered after platinum-based CRT is the established, global standard of care for unresectable Stage III NSCLC based on the PACIFIC Phase 3 trial results.
The PACIFIC-2 trial was initiated to evaluate concurrent Imfinzi administration with CRT to address patients who progress or discontinue treatment ...